India, June 2 -- Celcuity Inc. (CELC) stock fell 22.41 percent to $95.41, losing $27.55 on Tuesday, despite announcing detailed positive efficacy data from the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 clinical trial for gedatolisib.
The stock is currently trading at $95.41, compared to its previous close of $122.96 on the Nasdaq. During the session, it reached a high of $99.83 and a low of $94.32, with trading volume climbing to 1,383,663 shares, notably higher than its average daily volume of 938,892.
The sell-off occurred as the clinical-stage biotechnology company prepared to present late-breaking data on its breast cancer treatment candidate at the American Society of Clinical Oncology (ASCO) Annual Meeting. Though the study dem...